Phase II Dutasteride in Combination With CAB vs CAB in SDC
NCT05513365
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
26
Enrollment
OTHER
Sponsor class
Conditions
Salivary Duct Carcinoma
Interventions
DRUG:
Goserelin 10.8 mg
DRUG:
Bicalutamide 50 mg
DRUG:
Dutasteride 0.5 mg
Sponsor
Radboud University Medical Center
Collaborators
[object Object]